Morinaga Milk Industry Co., Ltd. announced that its proprietary probiotic strain Bifidobacterium longum subsp. longum BB536 (hereafter referred to as Bifidobacteriumlongum BB536) has obtained approval from the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria, ANVISA). This approval, granted on July 27, 2023, allows for the utilization of Bifidob bacterium longum BB536 in dietary supplements and conventional food products sold in Brazil.

The strain has also been registered in ANVISA's list of approved products. Bifidobacterium Longum BB536, a clinically effective and well-established multifunctional probiotic strain, has a history of over 50 years of human use, supported by more than 240 scientific studies as of March 2023. Bifidobacteria longum BB536 strain has been recognized globally as a leading functional probiotic ingredient, holding Generally Recognized as Safe (GRAS) status in the U.S. for use in conventional foods and infant formula.

It has also been approved as a "New Food Ingredient" in China for use in infant and toddler foods under the age of three. This approval aligns with the company's commitment to expanding its presence in international markets, including strengthening partnerships with major infant formula manufacturers and sales for dietary supplements all over the world. The Brazilian probiotic supplement market is growing rapidly, with a compound annual growth rate of approximately 9% from 2013 to 2022, and the market size has more than doubled to approximately USD 200 million.

Morinaga Milk anticipates a promising future in the Brazilian market.